Patterson, Dan M; Zweifel, Martin; Middleton, Mark R; Price, Patricia M; Folkes, Lisa K; Stratford, Michael R L; Ross, Phil; Halford, Sarah; Peters, Jane; Balkissoon, Jai; Chaplin, Dai J; Padhani, Anwar R; Rustin, Gordon J S (2012). Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clinical cancer research, 18(5), pp. 1415-25. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-2414
Full text not available from this repository.Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Zweifel, Martin |
ISSN: |
1078-0432 |
Publisher: |
American Association for Cancer Research |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:20 |
Last Modified: |
05 Dec 2022 14:05 |
Publisher DOI: |
10.1158/1078-0432.CCR-11-2414 |
PubMed ID: |
22235096 |
Web of Science ID: |
000301040700025 |
URI: |
https://boris.unibe.ch/id/eprint/6473 (FactScience: 211440) |
Actions (login required)
 |
Edit item |